Dr Reddy's Labs optimistic about Trump administration
Indian generic drugmaker Dr Reddys Laboratories expressed optimism about the Donald Trump administration on Thursday, citing the country would have an edge amid U.S-China tensions.
"I believe that the type of products that we bring in and the positioning of India is favorable," CEO Erez Israeli said in a press call, adding that the company's drugs in the U.S. market are cheaper than the current alternatives.
As per Reuters report, he said,"..This is very much what also I believe the U.S. administration wants."
Earlier in the day, the generic drugmaker reported consolidated net profit of 14.14 billion rupees ($163.7 million) for the quarter ended Dec. 31, missing analysts' estimate of 14.89 billion rupees as per data compiled by LSEG.
Indian generic drugmakers have been struggling with sales slowdown in the U.S., delayed approvals for new drug applications, and lower pricing amid stiff competition, according to analysts.
Revenue from North America, Dr Reddy's biggest geography, rose 1% to 33.80 billion rupees, as volume growth on the back of new launches was offset by lower prices.
"The sequential decline was largely on account of lower sales of certain products including Lenalidomide," the company said.
Lenalidomide, a major contributor to Dr Reddy's North America sales since 2022, is a generic version of Bristol-Myers Squibb's popular cancer treatment drug Revlimid.
Still, Reddy's total revenue climbed 16% to 83.81 billion rupees, beating analysts' estimate, boosted by a 14% growth in its India sales.
The growth was also aided by revenue from the company's in-licensed vaccine portfolio. Last year, Reddy's partnered with French drugmaker Sanofi for distribution of its vaccines in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.